Image shows the brain of an MS patient. In mice, PPARγ dampens Th17 responses and eases EAE.MEHAU KULYK/PHOTO RESEARCHERS, INC.Although Th17 cells help battle bacteria and viruses, they can also turn traitor and promote autoimmune attacks. Klotz et al. report a possible new way to stall development of these self-targeting cells.

Studies have implicated Th17cells in several autoimmune diseases, including multiple sclerosis. The master switch for Th17 differentiation is the transcription factor ROR*γ*t, but researchers know little about how cells control ROR*γ*t activity. Klotz et al. homed in on one possible regulator, the nuclear receptor PPAR*γ*, whose immune tasks range from quelling inflammation to inhibiting proliferation of T cells.

Mice lacking PPAR*γ* in their T cells developed severe EAE---the rodent equivalent of MS---more rapidly than did mice with normal T cells. Mice with PPAR*γ*-deficient T cells also harbored about three times as many autoreactive Th17 cells in the central nervous system. Stimulating PPAR*γ* with the synthetic molecule PIO ameliorated disease symptoms. In cultured T cells, the same treatment reduced ROR*γ*t expression.

These results suggest that PPAR*γ* hampers the differentiation of Th17 cells in mice. The receptor does the same in humans, as naive human T cells stimulated with PPAR*γ* agonists produced less IL-17 in culture. PPAR*γ* exerts its effects, the team discovered, by preventing the SMRT repressor from leaving the ROR*γ*t promoter in response to the Th17-promoting cytokines IL-6 and TGF-β.

PPAR*γ* is selective---it had no effect on differentiation of other cell types such as regulatory T cells or Th1 and Th2 T cells. That Th17 cells can be restrained without hobbling other immune cells is good news for potential PPAR*γ*-activating treatments. However, the authors caution that PPAR*γ* only soothed EAE symptoms, rather than eliminating the disease. They are now trying to pin down naturally occurring PPAR*γ* triggers and determine whether any of them malfunction during autoimmune diseases. Although the *α* and δ isoforms of PPAR also dampen EAE, they seem to have more of an effect on IFN-*γ*--producing Th1 cells than on Th17 cells, but what governs this specificity is not yet known.
